Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma

J. P. Duprat, A. L. Domingues, E. G. Coelho, R. M.L.V. Leal, K. Nishinari, Rogerio Neves

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Introduction: Merkel cell carcinoma (MCC) is a very rare and aggressive neoplasm. Due to its rarity, therapeutic guidelines are not well established, especially for regionally advanced disease. Hyperthermic isolated limb perfusion (HILP) with Melphalan and either with or without tumor necrosis factor-alpha (TNF-α) is becoming more common in clinical practice, yet the long-term response is not clear. Previous reports have established indications for treatment of unresectable MCC as well as the outcome of MCC patients receiving perfusion treatment in combination with other therapies (e.g., radiation). Method: A review was performed of the most important articles in MEDLINE from the last 20 years related to HILP and MCC. It was possible to collect all cases of HILP from the literature. Details of one case of MCC where HILP was administered was included in the literature review. Results: A total of nine cases of MCC receiving ILP were identified in the literature; of these, seven achieved a complete response, one a partial response and one no response. All five patients treated without TNF-α had a complete response. Of the four patients treated with TNF-α, two had complete, one partial and one no response. Conclusion: Based on the cases described, isolated limb perfusion is an acceptable option to treat regional advanced cases of MCC, and the use of TNF-α does not impact the overall response.

Original languageEnglish (US)
Pages (from-to)568-572
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume35
Issue number6
DOIs
StatePublished - Jun 1 2009

Fingerprint

Merkel Cell Carcinoma
Fever
Extremities
Perfusion
Drug Therapy
Tumor Necrosis Factor-alpha
Melphalan
MEDLINE
Radiotherapy
Therapeutics
Guidelines

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Duprat, J. P. ; Domingues, A. L. ; Coelho, E. G. ; Leal, R. M.L.V. ; Nishinari, K. ; Neves, Rogerio. / Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma. In: European Journal of Surgical Oncology. 2009 ; Vol. 35, No. 6. pp. 568-572.
@article{7f7627ec85e24b768dc0ea76227737fd,
title = "Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma",
abstract = "Introduction: Merkel cell carcinoma (MCC) is a very rare and aggressive neoplasm. Due to its rarity, therapeutic guidelines are not well established, especially for regionally advanced disease. Hyperthermic isolated limb perfusion (HILP) with Melphalan and either with or without tumor necrosis factor-alpha (TNF-α) is becoming more common in clinical practice, yet the long-term response is not clear. Previous reports have established indications for treatment of unresectable MCC as well as the outcome of MCC patients receiving perfusion treatment in combination with other therapies (e.g., radiation). Method: A review was performed of the most important articles in MEDLINE from the last 20 years related to HILP and MCC. It was possible to collect all cases of HILP from the literature. Details of one case of MCC where HILP was administered was included in the literature review. Results: A total of nine cases of MCC receiving ILP were identified in the literature; of these, seven achieved a complete response, one a partial response and one no response. All five patients treated without TNF-α had a complete response. Of the four patients treated with TNF-α, two had complete, one partial and one no response. Conclusion: Based on the cases described, isolated limb perfusion is an acceptable option to treat regional advanced cases of MCC, and the use of TNF-α does not impact the overall response.",
author = "Duprat, {J. P.} and Domingues, {A. L.} and Coelho, {E. G.} and Leal, {R. M.L.V.} and K. Nishinari and Rogerio Neves",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.ejso.2008.10.002",
language = "English (US)",
volume = "35",
pages = "568--572",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma. / Duprat, J. P.; Domingues, A. L.; Coelho, E. G.; Leal, R. M.L.V.; Nishinari, K.; Neves, Rogerio.

In: European Journal of Surgical Oncology, Vol. 35, No. 6, 01.06.2009, p. 568-572.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma

AU - Duprat, J. P.

AU - Domingues, A. L.

AU - Coelho, E. G.

AU - Leal, R. M.L.V.

AU - Nishinari, K.

AU - Neves, Rogerio

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Introduction: Merkel cell carcinoma (MCC) is a very rare and aggressive neoplasm. Due to its rarity, therapeutic guidelines are not well established, especially for regionally advanced disease. Hyperthermic isolated limb perfusion (HILP) with Melphalan and either with or without tumor necrosis factor-alpha (TNF-α) is becoming more common in clinical practice, yet the long-term response is not clear. Previous reports have established indications for treatment of unresectable MCC as well as the outcome of MCC patients receiving perfusion treatment in combination with other therapies (e.g., radiation). Method: A review was performed of the most important articles in MEDLINE from the last 20 years related to HILP and MCC. It was possible to collect all cases of HILP from the literature. Details of one case of MCC where HILP was administered was included in the literature review. Results: A total of nine cases of MCC receiving ILP were identified in the literature; of these, seven achieved a complete response, one a partial response and one no response. All five patients treated without TNF-α had a complete response. Of the four patients treated with TNF-α, two had complete, one partial and one no response. Conclusion: Based on the cases described, isolated limb perfusion is an acceptable option to treat regional advanced cases of MCC, and the use of TNF-α does not impact the overall response.

AB - Introduction: Merkel cell carcinoma (MCC) is a very rare and aggressive neoplasm. Due to its rarity, therapeutic guidelines are not well established, especially for regionally advanced disease. Hyperthermic isolated limb perfusion (HILP) with Melphalan and either with or without tumor necrosis factor-alpha (TNF-α) is becoming more common in clinical practice, yet the long-term response is not clear. Previous reports have established indications for treatment of unresectable MCC as well as the outcome of MCC patients receiving perfusion treatment in combination with other therapies (e.g., radiation). Method: A review was performed of the most important articles in MEDLINE from the last 20 years related to HILP and MCC. It was possible to collect all cases of HILP from the literature. Details of one case of MCC where HILP was administered was included in the literature review. Results: A total of nine cases of MCC receiving ILP were identified in the literature; of these, seven achieved a complete response, one a partial response and one no response. All five patients treated without TNF-α had a complete response. Of the four patients treated with TNF-α, two had complete, one partial and one no response. Conclusion: Based on the cases described, isolated limb perfusion is an acceptable option to treat regional advanced cases of MCC, and the use of TNF-α does not impact the overall response.

UR - http://www.scopus.com/inward/record.url?scp=67349189134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349189134&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2008.10.002

DO - 10.1016/j.ejso.2008.10.002

M3 - Review article

C2 - 19013049

AN - SCOPUS:67349189134

VL - 35

SP - 568

EP - 572

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 6

ER -